Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

BACKGROUND: There is increasing evidence that metastatic colorectal cancer (mCRC) is a genetically heterogeneous disease and that tumours arising from different sides of the colon (left versus right) have different clinical outcomes. Furthermore, previous analyses comparing the activity of different...

ver descrição completa

Detalhes bibliográficos
Autor principal: Arnold, D (author)
Outros Autores: Lueza, B (author), Douillard, J-Y (author), Peeters, M (author), Lenz, H-J (author), Venook, A (author), Heinemann, V (author), Van Cutsem, E (author), Pignon, J-P (author), Tabernero, J (author), Cervantes, A (author), Ciardiello, F (author)
Formato: article
Idioma:eng
Publicado em: 2018
Assuntos:
Anticorpos Monoclonais
Antineoplásicos Imunológicos
Bevacizumab
Cetuximab
Neoplasias Colorrectais
Genes ras
Antibodies, Monoclonal
Genes, ras
Antineoplastic Agents, Immunological
Colorectal Neoplasms
Texto completo:http://hdl.handle.net/10400.26/23016
País:Portugal
Oai:oai:comum.rcaap.pt:10400.26/23016

Texto Completo

http://hdl.handle.net/10400.26/23016

Registros relacionados